Dr. Gubens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
269 Campus Dr
# Division
Stanford, CA 94305Phone+1 650-723-6661
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2008 - 2011
University of California (San Francisco)Residency, Internal Medicine, 2005 - 2008
Stanford University School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2007 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Start of enrollment: 2020 May 29
Publications & Presentations
PubMed
- 375 citationsEvolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M. Blakely, Thomas B.K. Watkins, Wei Wu, Beatrice Gini, Jacob J. Chabon
Nature Genetics. 2017-11-06 - 617 citationsNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman
Journal of the National Comprehensive Cancer Network. 2022-05-01 - 32 citationsAdjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung CancerGavitt A. Woodard, Sue X. Wang, Johannes R. Kratz, Clara Zoon-Besselink, Chun-Yuan Chiang
Clinical Lung Cancer. 2018-01-01
Press Mentions
Conference Coverage: NCCN Clinical UpdatesApril 16th, 2019
ASCO 2017 – Lung Cancer – A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line TreatmentAugust 9th, 2017- ASCO 2017 – Lung Cancer – Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field – Is There a Place for Lorlatinib?August 9th, 2017
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
